5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderRecruitingPhase 32026-10-06NCT06136650
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerNon-muscle Invasive Bladder Cancer With Carcinoma in SituRecruitingPhase 32026-09-25NCT06545955
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderRecruitingPhase 32026-09-23NCT07085767
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)Metastatic Castrate Resistant Prostate Cancer (mCRPC)Active, not recruitingPhase 42026-07-06NCT04597125
AV Junction Ablation or Optimal Medical Treatment in PatiEnts With Cardiac Resynchronization Therapy and Permanent Atrial FibrillationArrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder, persistent atrial fibrillationRecruitingNot applicable2023-06-08NCT05776797